Optimizing Drug Therapy in Kidney Diseases: Effectiveness and Safety
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 92
Special Issue Editors
2. Personalized Medicine and Mental Health Unit (MEPER), Extremadura Biosanitary University Research Institute of Extremadura (INUBE), Av. de Elvas s/n., 06080 Badajoz, Spain
Interests: pharmacogenetics; pharmacogenomics; clinical pharmacology; personalized and precision medicine; psychopharmacology; nephropharmacology
Interests: tacrolimus; drug–drug interactions; pharmacotherapy of kidney diseases; drug-induced nephrotoxicity; pharmacokinetics
Special Issue Information
Dear Colleagues,
It is known that diabetes, hypertension, or glomerulonephritis are the cause of chronic kidney disease (CKD), which is classified as a civilization disease. Therefore, research into new drugs for the treatment of kidney diseases is needed. In recent years, biological treatment, including monoclonal antibodies, has been a revolution in nephrology. Chronic kidney disease is associated with disorders of pharmacokinetic processes, mainly at the stage of distribution or excretion of drugs. It is important to appropriately modify the dosage of drugs depending on the filtration function of the kidneys in order to maintain a therapeutic drug concentration and the safety of pharmacotherapy. Patients treated with renal replacement therapy (hemodialysis, peritoneal dialysis) require supplementation of doses to support the effectiveness of treatment. Patients after kidney transplantation take immunosuppressive drugs; polypharmacy increases the risk of drug–drug interactions. One of the tools for optimizing pharmacotherapy is therapeutic drug monitoring, which plays a key role in the group of patients with chronic kidney disease.
We invite researchers studying pharmacokinetics, pharmacodynamics, and drug–drug interactions in patients with kidney diseases to submit original research articles or review articles. The purpose of this Special Issue is to provide both researchers and clinicians with up-to-date information.
Dr. Pedro Dorado
Dr. Miłosz Miedziaszczyk
Dr. Ilona Idasiak-Piechocka
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug–drug interactions
- pharmacotherapy of kidney diseases
- immunosuppression
- drug-induced nephrotoxicity
- glomerulonephritis
- kidney transplantation
- hemodialysis
- peritoneal dialysis
- vasculitis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
